REGENXBIO INC (NASDAQ:RGNX) Reports Q2 2025 Earnings Miss, Stock Slides Amid Revenue and EPS Shortfalls

REGENXBIO INC (NASDAQ:RGNX) reported its second-quarter 2025 financial results, missing analyst expectations on both revenue and earnings per share (EPS). The company posted revenue of $21.36 million, falling short of the consensus estimate of $28.67 million, while its reported EPS of -$1.38 was worse than the anticipated -$1.122. The market reaction has been negative, with pre-market trading showing a decline of approximately 2.3%, extending a broader downward trend over the past month, where the stock has dropped around 10.25%.

Key Financial Takeaways

• Revenue Miss: Reported revenue of $21.36M vs. $28.67M expected (25.5% below estimates).
• Wider Loss Per Share: EPS of -$1.38 compared to the -$1.122 estimate.
• Market Reaction: Continued downward pressure, with pre-market losses following a 10.2% decline over the past month.

Operational Highlights from the Earnings Report

The company provided updates on its clinical pipeline, emphasizing progress in two key programs:

1. RGX-202 for Duchenne Muscular Dystrophy (DMD): The pivotal trial enrollment has accelerated, with topline results expected in the first half of 2026 and a Biologics License Application (BLA) submission targeted for mid-2026.
2. Surabgene Lomparvovec for Diabetic Retinopathy: A pivotal Phase IIb/III trial will be initiated using suprachoroidal delivery, alongside new Phase II ALTITUDE trial data.

While these developments signal continued progress in REGENXBIO’s gene therapy pipeline, the financial underperformance appears to be the dominant factor influencing investor sentiment.

Forward-Looking Estimates

Analyst expectations for the full year 2025 project sales of $355.88 million, with Q3 2025 revenue estimates at $112.22 million. The company did not provide explicit guidance in its press release, leaving investors to rely on external forecasts. Given the Q2 miss, market participants may be reassessing the likelihood of REGENXBIO meeting full-year projections.

For a deeper dive into earnings estimates and historical performance, see REGENXBIO’s earnings and estimates page.

Disclaimer: This article is not investment advice. Investors should conduct their own research or consult a financial advisor before making decisions.